Literature DB >> 26908154

Prepregnancy obesity: a risk factor for future development of ovarian and breast cancer.

Roy Kessous1, Ehud Davidson, Mihai Meirovitz, Ruslan Sergienko, Eyal Sheiner.   

Abstract

The aim of this study was to investigate the association between a history of prepregnancy obesity and a woman's future long-term risk for the development of female malignancies. A population-based study compared the incidence of long-term female malignancies in a cohort of consecutive women with and without a diagnosis of prepregnancy obesity. Deliveries occurred between the years 1988 and 2013, with a mean follow-up duration of 11.6 years. Women with known malignancies before the index pregnancy and known genetic predisposition for malignancy were excluded from the study. Female malignancies were divided according to specific type (ovary, uterine, breast, and uterine cervix). A Kaplan-Meier survival curve was used to estimate the cumulative incidence of malignancies. A Cox proportional hazards model was used to estimate the adjusted hazard ratios for female malignancy. During the study period, 106 251 deliveries fulfilled the inclusion criteria; 2.2% (n=2360) occurred in patients with a history of prepregnancy obesity. During the follow-up period, patients with prepregnancy obesity had a significantly increased risk for hospitalization because of female malignancies as a group and specifically ovarian and breast cancer. Using a Kaplan-Meier survival curve, patients with a previous diagnosis of prepregnancy obesity had a significantly higher cumulative incidence of female malignancies. Using a Cox proportional hazards model, adjusted for confounders such as gestational diabetes mellitus and maternal age, prepregnancy obesity remained independently associated with long-term risk for female malignancies (adjusted hazard ratio: 1.4; 95% confidence interval: 1.1-1.9; P=0.045). Prepregnancy obesity is an independent risk factor for long-term female malignancies such as ovarian and breast cancer.

Entities:  

Mesh:

Year:  2017        PMID: 26908154     DOI: 10.1097/CEJ.0000000000000228

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  6 in total

Review 1.  The Role of the Adipokine Resistin in the Pathogenesis and Progression of Epithelial Ovarian Cancer.

Authors:  Klaudia Parafiniuk; Wiktoria Skiba; Anna Pawłowska; Dorota Suszczyk; Aleksandra Maciejczyk; Iwona Wertel
Journal:  Biomedicines       Date:  2022-04-16

2.  Association between maternal prepregnancy obesity and breastfeeding duration: Data from a nationwide prospective birth cohort.

Authors:  Julie Boudet-Berquier; Benoit Salanave; Jean-Claude Desenclos; Katia Castetbon
Journal:  Matern Child Nutr       Date:  2017-08-29       Impact factor: 3.092

3.  The dynamic changes in the pattern of liver function tests in pregnant obese women.

Authors:  Cristina Oana Daciana Teodorescu; Florica Șandru; Adham Charkaoui; Andrei Teodorescu; Amorin Remus Popa; Andreea-Iuliana Miron
Journal:  Exp Ther Med       Date:  2021-07-13       Impact factor: 2.447

Review 4.  Epidemiological characteristics of and risk factors for breast cancer in the world.

Authors:  Zohre Momenimovahed; Hamid Salehiniya
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-04-10

5.  Mother-child cardiometabolic health 4-10 years after pregnancy complicated by obesity with and without gestational diabetes.

Authors:  Samantha L Martin; Li Zhang; Makenzie L Callahan; Jessica Bahorski; Cora E Lewis; Bertha A Hidalgo; Nefertiti Durant; Lorie M Harper; Ashley N Battarbee; Kirk Habegger; Bethany A Moore; Alysha Everett; Stella Aslibekyan; Rogerio Sertie; Nengjun Yi; W Timothy Garvey; Paula Chandler-Laney
Journal:  Obes Sci Pract       Date:  2022-02-16

6.  Maternal Obesity and Offspring Long-Term Infectious Morbidity.

Authors:  Gil Gutvirtz; Tamar Wainstock; Daniella Landau; Eyal Sheiner
Journal:  J Clin Med       Date:  2019-09-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.